Gufic Biosciences Appoints M/s. Poddar & Co. as Cost Auditors, Mrs. Saroj Kirdolia as Internal Auditor
Gufic Biosciences Limited's Board of Directors re-appointed M/s. Poddar & Co. as Cost Auditors for FY 2026-27. Mrs. Saroj R. Kirdolia was appointed as Internal Auditor for the same financial year. Both appointments were approved on May 29, 2026.
The appointment of cost and internal auditors is a routine compliance activity for a listed company and is unlikely to have a significant immediate impact on the company's financial performance or stock price.
The announcement pertains to routine appointments of auditors, which are standard corporate governance procedures and do not inherently suggest a positive or negative shift in the company's performance or outlook.
Gufic Biosciences Limited announced key appointments following its Board of Directors meeting held on Friday, May 29, 2026. The Board approved the re-appointment of M/s. Poddar & Co., Cost Accountants (Firm Registration No. 101734), as the Cost Auditors for the Financial Year 2026-27.
Additionally, Mrs. Saroj R. Kirdolia has been appointed as the Internal Auditor of the Company, effective from the Financial Year 2026-27. She will hold office until her employment with the Company ceases or as otherwise decided by the Board.
M/s. Poddar & Co. is a specialized Cost Accounting firm with significant experience across various industries. Mrs. Saroj R. Kirdolia is a Chartered Accountant with over 7 years of experience in auditing and taxation, and has been associated with Gufic Biosciences for the past 6 years, focusing on evaluating internal controls and business processes.
The Board meeting commenced at 7:30 p.m. and concluded at 9:05 p.m.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under auditor changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.